Sera Prognostics (NASDAQ:SERA) Shares Down 3.6% – What’s Next?

Shares of Sera Prognostics, Inc. (NASDAQ:SERA) fell 3.6% on Thursday . The stock traded as low as $2.96 and last traded at $2.98. 25,728 shares were traded during trading, a decline of 28% from the average session volume of 35,732 shares. The stock had previously closed at $3.09.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on SERA. Weiss Ratings restated a “sell (d-)” rating on shares of Sera Prognostics in a research note on Monday. Wall Street Zen upgraded Sera Prognostics from a “sell” rating to a “hold” rating in a research note on Saturday, October 25th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Sera Prognostics presently has a consensus rating of “Sell”.

Sera Prognostics Price Performance

The stock’s fifty day simple moving average is $3.17 and its 200-day simple moving average is $2.75. The stock has a market cap of $115.03 million, a P/E ratio of -3.87 and a beta of 0.97.

Sera Prognostics (NASDAQ:SERA) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.03. The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.10 million. Sera Prognostics had a negative return on equity of 41.69% and a negative net margin of 34,343.16%. Analysts forecast that Sera Prognostics, Inc. will post -0.96 EPS for the current year.

Insider Transactions at Sera Prognostics

In other news, CEO Zhenya Lindgardt sold 21,158 shares of the business’s stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $3.15, for a total transaction of $66,647.70. Following the completion of the transaction, the chief executive officer owned 811,136 shares of the company’s stock, valued at approximately $2,555,078.40. The trade was a 2.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders sold 46,933 shares of company stock valued at $147,672 in the last quarter. Company insiders own 13.50% of the company’s stock.

Institutional Investors Weigh In On Sera Prognostics

A number of hedge funds and other institutional investors have recently modified their holdings of SERA. XTX Topco Ltd bought a new position in Sera Prognostics in the 1st quarter valued at about $39,000. Abel Hall LLC acquired a new stake in shares of Sera Prognostics in the 2nd quarter worth approximately $31,000. Wagner Wealth Management LLC bought a new position in shares of Sera Prognostics in the second quarter valued at approximately $34,000. Vanguard Personalized Indexing Management LLC bought a new position in shares of Sera Prognostics in the third quarter valued at approximately $38,000. Finally, Riverview Capital Advisers LLC acquired a new position in shares of Sera Prognostics during the second quarter valued at approximately $35,000. 54.64% of the stock is currently owned by institutional investors.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.